Hualan Biological Engineering (SZSE:002007) Net Income From Continuing Operations : ¥1,654 Mil (TTM As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Hualan Biological Engineering Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Hualan Biological Engineering's net income from continuing operations for the three months ended in Mar. 2024 was ¥274 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was ¥1,654 Mil.

Hualan Biological Engineering Net Income From Continuing Operations Historical Data

The historical data trend for Hualan Biological Engineering's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hualan Biological Engineering Net Income From Continuing Operations Chart

Hualan Biological Engineering Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

1,378.88

1,844.16

1,454.12

1,247.60

1,761.69

Hualan Biological Engineering Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															382.37	179.74	710.18	489.40	274.37

Hualan Biological Engineering Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,654 Mil.

Hualan Biological Engineering (SZSE:002007) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hualan Biological Engineering Inc (SZSE:002007) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

N/A

Address

No. A1 Hualan Avenue, Henan Province, Xinxiang, CHN, 453003

Website

http://www.hualanbio.com

Hualan Biological Engineering Inc is a China-based biopharmaceutical company. It is engaged in the research, development, production, and commercialization of plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics. The plasma products offered by the company include Human albumin, Human fibrinogen, Human tetanus immunoglobulin and others. The vaccines products include Recombinant hepatitis B vaccine, Inactivated influenza vaccine and other. It also offers gene products such as Monoclonal Antibody for tumor, autoimmune diseases, infectious diseases, transplant rejection, and Recombinant monoclonal antibodies.

Executives

An Kang	Directors, executives
Pan Ruo Wen	Executives
An Wen Qi	Executives
Wang Qi Ping	Directors, executives
Fan Bei	Directors, executives
Ma Xiao Wei	Executives
Xie Jun Min	Directors, executives
Zhang Bao Xian	Executives
Lv Cheng Yu	Securities Affairs Representative
Zhang Jin Gang	Independent director
Wang Li Ting	Independent director
Ma Li	Supervisors
Sun Zhen Guo	Supervisors
Chen Lei Shan	Supervisors
Yang Bao Ping	Supervisors

Hualan Biological Engineering (SZSE:002007) Headlines

No Headlines